Efficacy of Vonoprazan combined with high-dose Amoxicillin for eradication of <i>Helicobacter pylori</i>
Objective To evaluate clinical efficacy of the combination of Vonoprazan and high-dose Amoxicillin in the initial eradication treatment of <i>Helicobacter pylori</i> （Hp）. Methods Select 200 patients with Hp infection who have not undergone Hp eradication treatment in the past as the re...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of New Medicine
2024-03-01
|
| Series: | Xin yixue |
| Subjects: | |
| Online Access: | https://www.xinyixue.cn/fileup/0253-9802/PDF/1712537313853-988765878.pdf |
| Summary: | Objective To evaluate clinical efficacy of the combination of Vonoprazan and high-dose Amoxicillin in the initial eradication treatment of <i>Helicobacter pylori</i> （Hp）. Methods Select 200 patients with Hp infection who have not undergone Hp eradication treatment in the past as the research subjects. All patients were randomly divided into the observation group （<i>n = </i>100） and control group （<i>n = </i>100） using random number table method. In the observation group， a combination regimen of Vonoprazan （20 mg twice a day） and Amoxicillin （1 g three times a day） was given for 14 days. In the control group， a bismuth quadruple therapy was delivered for 14 days， which included Esomeprazole （20 mg twice a day）， Bismuth Potassium Citrate （220 mg twice a day）， Amoxicillin （1 g twice a day） and Clarithromycin （0.5 g twice a day）. The Hp eradication rate and incidence of adverse reactions after medication were compared between two groups. Results Of 200 patients， 11 patients were excluded from subsequent analysis， including 8 cases lost to follow-up and 3 cases with poor compliance of medication. The remaining 189 patients （96 in the observation group and 93 in the control group） completed the entire procedure. According to intention-to-treat （ITT） and per-protocol （PP） set analyses， the Hp eradication rate in the observation group was significantly higher than that in the control group （91.0% <i>vs</i>. 79.0%， <i>P</i><sub>ITT </sub>=0.017； 94.8% <i>vs.</i> 84.9%， <i>P</i><sub>PP</sub>= 0.024）. The incidence of adverse reactions did not significantly differ between two groups （4% <i>vs</i>. 5%，<i>χ</i> <sup>2</sup> < 0.001，<i>P > </i>0.999）. Conclusion The combination therapy of Vonoprazan and high-dose Amoxicillin is an efficacious and safe therapeutic option for patients with initial Hp infection， which is worthy of promotion in grassroot-level hospitals. |
|---|---|
| ISSN: | 0253-9802 |